220 results on '"Freilone, Roberto"'
Search Results
2. Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice
3. Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study
4. Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial
5. Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
6. Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial
7. Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
8. Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The STRIDER study.
9. Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience
10. Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions
11. Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax
12. P1171: CNS RELAPSE OF DIFFUSE LARGE B-CELL LYMPHOMA. CLINICAL PRESENTATION, OUTCOME AND ROLE OF UPFRONT PROPHYLAXIS: A 10-YEAR SINGLE CENTER EXPERIENCE.
13. P678: EARLY WARNING RESPONSES IN CML PATIENTS: A REAL-LIFE TURIN EXPERIENCE
14. PB2057: THE COMBINATION OF ANTI-COMPLEMENT THERAPY AND CYCLOSPORINE +/- ELTROMBOPAG IN PNH IS EFFECTIVE AND SAFE: A REAL-LIFE OBSERVATIONAL STUDY.
15. Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors
16. Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation
17. Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions.
18. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience
19. Validation of National Early Warning Score (News) and Quick Sequential ( Sepsis‐Related ) Organ Failure Assessment (Qsofa) in Acute Myeloid Leukaemia Patients Treated with Intensive Chemotherapy
20. Levofloxacin prophylaxis omission in acute myeloid leukemia during post induction aplasia: a single center study
21. Validation of National Early Warning Score and Quick Sequential (sepsis‐related) Organ Failure Assessment in acute myeloid leukaemia patients treated with intensive chemotherapy.
22. Additional file 1 of Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial
23. Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature
24. Levofloxacin Prophylaxis Versus no Prophylaxis in Acute Myeloid Leukemia During Post-Induction Aplasia: a Single Center Study.
25. Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021
26. Philadelphia-Negative MPN: A Molecular Journey, from Hematopoietic Stem Cell to Clinical Features
27. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin’s lymphoma patients: A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL)
28. Expected survival of cancer and myeloma patients undergoing bisphosphonates or denosumab. Potential impact on diagnosis and management of Osteonecrosis of Jaws (ONJ)
29. OSTEONECROSIS OF THE JAW (ONJ) IN CANCER AND MYELOMA PATIENTS. A 16-YEAR EXPERIENCE OF “RETE ONCOLOGICA PIEMONTE–VALLE D’AOSTA” CANCER NETWORK
30. Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice
31. A brief rituximab, bendamustine, mitoxantrone (R‐BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL)
32. Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes
33. Management of Oral Hydroxyurea-Related Ulcers: A Cases Series
34. Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)
35. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia
36. Clinical Outcomes of 420 MDS Patients Treated with 5-Azacytidine: Evaluation of Overall Survival, Duration of Treatment and Rate of Discontinuation in a Real Life Study from the Italian MDS Registry of Fondazione Italiana Sindromi Mielodisplastiche (FISM)
37. Radiotherapy Consolidation Reduces Risk of Relapse in Diffuse Large B-Cell Lymphoma Patients with Bulky Disease in Complete Response after Frontline Immunochemotherapy: Results from a Retrospective Single Center Study
38. Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
39. Interim Positron Emission Tomography Response–Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study
40. The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL)
41. The Prognostic Value of MYC, BCL2 and BCL6 Overexpression Evaluated By Immunohistochemistry (IHC) in De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP
42. A Real Life Survey On Erythropoietin Alpha Treatment In a Cohort Of 1049 Low Risk MDS Patients: An Italian MDS Registry Study
43. Role Of Interim,-PET In Poor Prognosis Young Patients With Diffuse Large B Cell Lymphoma At Diagnosis: Data From An Ancillary Study Of a Prospective Randomized Phase III Study (DLCL04) From the Fondazione Italiana Linfomi
44. Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL).
45. R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL).
46. Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma(FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi
47. The Use of FDG-PET in the Initial Staging of Patients with Follicular Lymphoma (FL). A Retrospective Study From the Fondazione Italiana Linfomi
48. Radioimmunotherapy (RIT) with 90yttrium Zevalin Followed by BEAM Conditioning Regimen (Z-BEAM) and Autologous Stem Cell Transplantation (ASCT) for the Treatment of High Risk Relapsed/Resistant Non Hodgkin's Lymphoma (NHL)
49. Prognostic Impact of Comorbidities In A Cohort of 788 MDS Patients Based On A CIRS-G Derived Score. A MDS Piedmont Registry Prospective Study
50. Prolonged Survival with Low Incidence of CNS Relapse and Late Toxicities in a Retrospective Series of 278 Young Patients with High-Risk (aa-IPI 2–3) Diffuse Large B-Cell Lymphoma Treated with Intensified Chemotherapy with or without Rituximab At Diagnosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.